Azapeptides and their therapeutic potential

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Gray CJ, Quibell M, Baggett N, Hammerle T. Incorporation of azaglutamine residues into peptides synthesised by the ultra-high load solid (gel)-phase technique. Int. J. Peptide Protein Res.40(5),351–362 (1992).
  Medline CASGoogle Scholar
• 2  Liley M, Johnson T. Solid phase synthesis of azapeptides utilising reversible amide bond protection to prevent hydantoin formation. Tetrahedron Lett.41(20),3983–3985 (2000).
  CASGoogle Scholar
• 3  Ahn IA, Woong Kim S, Ro S. Solid phase synthesis of azapeptides using an automatic synthesizer. Mol. Divers.4(1),23–24(1998).
  Medline CASGoogle Scholar
• 4  Verhelst SHL, Witte MD, Arastu-Kapur S, Fonovic M, Bogyo M. Novel aza peptide inhibitors and active-site probes of papain-family cysteine proteases. Chem. Bio. Chem.7(6),943–950 (2006).
  Medline CASGoogle Scholar
• 5  Melendez RE, Lubell WD. Aza-amino acid scan for rapid identification of secondary structure based on the application of N-Boc-aza¹-dipeptides in peptide synthesis. J. Am. Chem. Soc.126(21),6759–6764 (2004).▪ Strategy developed for aza amino acid scanning.
  Medline CASGoogle Scholar
• 6  Nowick JS, Powell NA, Nguyen TM, Noronha G. An improved method for the synthesis of enantiomerically pure amino acid ester isocyanates. J. Org. Chem.57(26),7364–7366 (1992).
  CASGoogle Scholar
• 7  André F, Marraud M, Tsouloufis T, Tzartos SJ, Boussard G. Triphosgene: an efficient carbonylating agent for liquid and solid-phase aza-peptide synthesis. Application to the synthesis of two aza-analogues of the AChR MIR decapeptide. J. Pept. Sci.3(6),429–441 (1997).
  Medline CASGoogle Scholar
• 8  Frochot C, Vanderesse R, Driou A, Linden G, Marraud M, Thong Cung M. A solid-phase synthesis of three aza-, iminoaza- and reduced aza-peptides from the same precursor. Lett. Pept. Sci.4(4),219–225 (1997).
  CASGoogle Scholar
• 9  Bourguet CB, Proulx C, Klocek S, Sabatino D, Lubell WD. Solution-phase submonomer diversification of aza-dipeptide building blocks and their application in aza-peptide and aza-DKP synthesis. J. Pept. Sci.16(6),284–296 (2010).
  Medline CASGoogle Scholar
• 10  Sabatino D, Proulx C, Klocek S et al. Exploring side-chain diversity by submonomer solid-phase aza-peptide synthesis. Org. Lett.11(16),3650–3653 (2009).▪▪ Introduction to the submonomer azapeptide synthesis approach.
  Medline CASGoogle Scholar
• 11  Gibson C, Goodman SL, Hahn D, Holzemann G, Kessler H. Novel solid-phase synthesis of azapeptides and azapeptoides via FMOC-strategy and its application in the synthesis of RGD-mimetics. J. Org. Chem.64(20),7388–7394 (1999).
  CASGoogle Scholar
• 12  Sulyok GAG, Gibson C, Goodman, SL, Hölzemann G, Wiesner M, Kessler H. Solid-phase synthesis of a nonpeptide RGD mimetic library: new selective avb3 integrin antagonists. J. Med. Chem.44(12),1938–1950 (2001).
  Medline CASGoogle Scholar
• 13  Malachowski WP, Tie C, Wang K, Broadrup RL. The synthesis of azapeptidomimetic β-lactam molecules as potential protease inhibitors. J. Org. Chem.67(25),8962–8969 (2002).
  Medline CASGoogle Scholar
• 14  Boeglin D, Lubell WD. Aza-amino acid scanning of secondary structure suited for solid-phase peptide synthesis with fmoc chemistry and aza-amino acids with heteroatomic side chains. J. Comb. Chem.7(6),864–878 (2005)
  Medline CASGoogle Scholar
• 15  Boeglin D, Xiang Z, Sorenson NB, Wood MS, Haskell-Luevano C, Lubell WD. Aza-scanning of the Potent melanocortin receptor agonist Ac-His-D-Phe-Arg-Trp-NH₂. Chem. Biol. Drug Des.67(4),275–283 (2006).
  Medline CASGoogle Scholar
• 16  Freeman NS, Hurevich M, Gilon C. Synthesis of N´-substituted Ddz-protected hydrazines and their application in solid phase synthesis of aza-peptides. Tetrahedron65(8),1737–1745 (2009).
  CASGoogle Scholar
• 17  Han H, Janda KD. Azatides: solution and liquid phase syntheses of a new peptidomimetic. J. Am. Chem. Soc.118(11),2539–2544 (1996).
  CASGoogle Scholar
• 18  Han H, Yoon J, Janda KD. Investigations of azapeptides as mimetics of Leu-enkephalin. Bioorg. Med. Chem. Lett.8(1),117–120 (1998).
  Medline CASGoogle Scholar
• 19  Hansen TK. Synthesis of azapeptides from hindered amines leading to novel growth hormone secretagogues. Tetrahedron Lett.40(51),9119–9120 (1999).
  CASGoogle Scholar
• 20  Randolph JT, Zhang X, Huang PP et al. Synthesis, antiviral activity, and conformational studies of a P3 aza-peptide analog of a potent macrocyclic tripeptide HCV protease inhibitor. Bioorg. Med. Chem. Lett.18(8),2745–2750 (2008).
  Medline CASGoogle Scholar
• 21  André F, Boussard G, Bayeul D, Didierjean C, Aubry A, Marraud M. Aza-peptides II. X-ray structures of aza-alanine and aza-asparagine-containing peptides. J. Pept. Res.49(6),556–562 (1997).
  Medline CASGoogle Scholar
• 22  Zega A, Mlinsek G, Sepic P et al. Design and structure–activity relationship of thrombin inhibitors with an azaphenylalanine scaffold: potency and selectivity enhancements via P2 optimization. Bioorg. Med. Chem.9(10),2745–2756 (2001).
  Medline CASGoogle Scholar
• 23  Bailey MD, Halmos T, Goudreau N, Lescop E, Llinàs-Brunet M. Novel azapeptide inhibitors of hepatitis C virus serine protease. J. Med. Chem.47(15),3788–3799 (2004).
  Medline CASGoogle Scholar
• 24  Wieczerzak E, Drabik P, Łankiewicz L et al. Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J. Med. Chem.45(19),4202–4211(2002).
  Medline CASGoogle Scholar
• 25  Mhidia R, Melnyk O. Selective cleavage of an azaGly peptide bond by copper(II). Long-range effect of histidine residue. J. Pept. Sci.16(3),141–147(2010).
  Medline CASGoogle Scholar
• 26  Boeglin D, Hamdan FF, Melendez RE et al. Calcitonin gene-related peptide analogues with aza and indolizidinone amino acid residues reveal conformational requirements for antagonist activity at the human calcitonin gene-related peptide 1 receptor. J. Med. Chem.50(6),1401–1408(2007).
  Medline CASGoogle Scholar
• 27  Proulx C, Lubell WD. Solid-phase synthesis of aza-proline analogs of GHRP-6. Peptides: Breaking Away. Proceedings of the 21st American Peptide Symposium. Lebl M (Ed.). Prompt Scientific Publishing, San Diego, CA, USA 56–57 (2009).
  Google Scholar
• 28  Semple JE, Rowley DC, Brunck TK, Ripka WC. Synthesis and biological activity of P2-P4 azapeptidomimetic P1-argininal and P1-ketoargininamide derivatives: a novel class of serine protease inhibitors. Bioorg. Med. Chem. Lett.7(3),315–320 (1997).
  CASGoogle Scholar
• 29  Zouikri M, Vicherat A, Aubry A, Marraud M, Boussard G. Azaproline as a β-turn-inducer residue opposed to proline. J. Pept. Res.52(1),19–26(1998).
  Medline CASGoogle Scholar
• 30  de los Santos JM, Lopez Y, Aparicio D, Palacios F. A convenient synthesis of substituted pyrazolidines and azaproline derivatives through highly regio- and diastereoselective reduction of 2-pyrazolines. J. Org. Chem.73(2),550–557 (2007).
  MedlineGoogle Scholar
• 31  Mish MR, Guerra FM, Carreira EM. Asymmetric dipolar cycloadditions of Me₃SiCHN₂. Synthesis of a novel class of amino acids: azaprolines. J. Am. Chem. Soc.119(35),8379–8380 (1997).
  CASGoogle Scholar
• 32  O’Donnell MJ, Zhou C, Scott WL. Solid-phase unnatural peptide synthesis (UPS). J. Am. Chem. Soc.118(25),6070–6071 (1996).
  Google Scholar
• 33  Bourguet CB, Sabatino D, Lubell WD. Benzophenone semicarbazone protection strategy for synthesis of aza-glycine containing aza-peptides. Pept. Sci.90(6),824–831(2008).
  CASGoogle Scholar
• 34  Proulx C, Lubell WD. Aza-1,2,3-triazole-3-alanine synthesis via copper-catalyzed 1,3-dipolar cycloaddition on aza-progargylglycine. J. Org. Chem.75(15),5385–5387(2010).
  Medline CASGoogle Scholar
• 35  Proulx C, Lubell WD. Copper-catalyzed N-arylation of semicarbazones for the synthesis of aza-arylglycine-containing aza-peptides. Org. Lett.12(13),2916–2919 (2010).
  Medline CASGoogle Scholar
• 36  Gante J, Neunhoeffer H, Schmidt A. Peptide analog systems. 9. Synthesis of 1,2,4-triazines. 16. bridged azapeptides, a class of novel 1,4,5,6-tetrahydro-1,2,4-triazin-3(2H)ones. J. Org. Chem.59(21),6487–6489 (1994).
  CASGoogle Scholar
• 37  Dyker H, Scherkenbeck J, Gondol D, Goehrt A, Harder A. Azadepsipeptides: synthesis and evaluation of a novel class of peptidomimetics. J. Org. Chem.66(11),3760–3766 (2001).
  Medline CASGoogle Scholar
• 38  Thormann M, Hofmann HJ. Conformational properties of azapeptides. J. Mol. Struct. (Theochem).469(1–3),63–76 (1999).
  CASGoogle Scholar
• 39  Jeffrey GA. The structures of some small molecules. Ab initio molecular orbital calculations versus low temperature neutron diffraction crystal structure analyses. J. Mol. Struct. (Theochem).108(1–2),1–15 (1984).
  Google Scholar
• 40  Ramondo F, Bencivenni L. Molecular conformation of isolated and hydrogen bonded N,N´-diformohydrazide: an ab initio study. J. Chem. Soc. Perkin Trans. 2.9,1797–1804 (1995).
  Google Scholar
• 41  Reynolds CH, Hormann E. Theoretical study of the structure and rotational flexibility of diacylhydrazines: implications for the structure of nonsteroidal ecdysone agonist and azapeptides. J. Am. Chem. Soc.118(39),9395–9401 (1996).
  CASGoogle Scholar
• 42  Chakravorty S, Reynolds CH. Improved AMBER torsional parameters for the N-N rotational barrier in diacylhydrazines. J. Mol. Graphics Mod.17,315–324 (1999).
  Medline CASGoogle Scholar
• 43  Bryantsev VS, Firman TK, Hay BP. Conformational analysis and rotational barriers of alkyl- and phenyl-substituted urea derivatives. J. Phys. Chem. A.109(5),832–842 (2005).
  Medline CASGoogle Scholar
• 44  Semetey V, Hemmerlin C, Didierjean C et al. Unexpected stability of the urea cis-trans isomer in urea-containing model pseudopeptides. Org. Lett.3(24),3843–3846 (2001).
  Medline CASGoogle Scholar
• 45  Bishop GJ, Price BJ, Sutherland IO. Torsional barriers in N,N´-diacylhydrazines. J. Chem. Soc. Chem. Commun.14,672–674 (1967).
  Google Scholar
• 46  Fletcher JR, Sutherland IO. Conformational changes in tetra-alkylhydrazines. J. Chem. Soc. Chem. Commun.13,706–708 (1969).
  Google Scholar
• 47  Lee HJ, Lee MH, Choi YS, Park HM, Lee KB. NBO approach to evaluate origin of rotational barrier of diformylhydrazine. J. Mol. Struct. (Theochem).631(1–3),101–110 (2003).
  CASGoogle Scholar
• 48  Lee HJ, Lee KB, Ahn IA, Ro S, Choi KH, Choi YS. Role of azaamino acid residue in β-turn formation and stability in designed peptide. J. Pept. Res.56(1),35–46 (2000).
  Medline CASGoogle Scholar
• 49  Ro S, Yoon CJ. Conformational preference of acetyl-azaalanine-N-methyl amide. Z. Phys. Chem.214(12),1699–1706 (2000).
  CASGoogle Scholar
• 50  Lee HJ, Choi KH, Ahn IA et al. The β-turn preferential solution conformation of a tetrapeptide containing an azaamino acid residue. J. Mol. Struct.569(1–3),43–54 (2001).
  CASGoogle Scholar
• 51  Lee HJ, Song JW, Choi, YS, Park HM, Lee KB. A theoretical study of conformational properties of N-methyl azapeptide derivatives. J. Am. Chem. Soc.124(40),11881–11893 (2002).
  Medline CASGoogle Scholar
• 52  Lee HJ, Jung HJ, Kim JH, Park HM, Lee KB. Conformational preference of azaglycine-containing dipeptides studied by PCM and IPCM methods. Chem. Phys.294(2),201–210 (2003).
  CASGoogle Scholar
• 53  Lee HJ, Park HM, Lee KB. The β-turn scaffold of tripeptide containing an azaphenylalanine residue. Biophys. Chem.125(1),117–126 (2007).
  Medline CASGoogle Scholar
• 54  Richardson JS. The anatomy and taxonomy of protein structure. Adv. Protein Chem.34,167–339 (1981).
  Medline CASGoogle Scholar
• 55  Hutchinson EG, Thornton JM. A revised set of potentials for β-turn formation in proteins. Protein Sci.3,2207–2216 (1994).
  Medline CASGoogle Scholar
• 56  Zhang WJ, Berglund A, Kao JL, Couty JP, Gershengorn MC, Marshall GR. Impact of azaproline on amide cis-trans isomerism: conformational analyses and NMR studies of model peptides including TRH analogues. J. Am. Chem. Soc.125(5),1221–1235 (2003).
  Medline CASGoogle Scholar
• 57  Che Y, Marshall GR. Impact of azaproline on peptide conformation. J. Org. Chem.69(26),9030–9042 (2004).
  Medline CASGoogle Scholar
• 58  André F, Vicherat A, Boussard G, Aubry A, Marraud M. Aza-peptides. III. Experimental structural analysis of aza-alanine and aza-asparagine-containing peptides. J. Pept. Res.50(5),372–381 (1997).
  Medline CASGoogle Scholar
• 59  Lecoq A, Boussard G, Marraud M, Aubry A. Crystal state conformation of three azapeptides containing the azaproline residue, a β-turn regulator. Biopolymers33(7),1051–1059 (1993).
  CASGoogle Scholar
• 60  Marraud M, Aubry A. Crystal structures of peptides and modified peptides. Pept. Sci.40(1),45–83 (1996).▪ Review containing x-ray analyses of azapeptides.
  CASGoogle Scholar
• 61  Benatalah Z, Aubry A, Boussard G, Marraud M. Evidence for a β-turn in an azadipeptide sequence. Synthesis and crystal structure of ButCO-Pro-AzaAla-NHPri. Int. J. Pept. Protein. Res.38(6),603–605 (1991).
  Medline CASGoogle Scholar
• 62  Gante J, Krug M, Lauterbach G, Weitzel R, Hiller W. Synthesis and properties of the first all-aza analogue of a biologically active peptide. J. Pept. Sci.1(3),201–206 (1995).
  Medline CASGoogle Scholar
• 63  Hemmerlin C, Cung MT, Boussard G. Synthesis and conformational preferences in solution and crystalline states of an aza-tripeptide. Tetrahedron Lett.42(30),5009–5012 (2001).
  CASGoogle Scholar
• 64  André F, Marraud M, Boussard G. Synthesis and structure of azasx-pro-containing aza-peptides. Tetrahedron Lett.37(2),183–186 (1996).
  CASGoogle Scholar
• 65  Bac A, Rivoal K, Cung M et al. Conformational disturbance induced by AzPro/Pro substitution in peptides. Lett. Pept. Sci.4(4),251–258 (1997).
  CASGoogle Scholar
• 66  Kelly SM, Jess TC, Price NC. How to study proteins by circular dichroism. Biochim. Biophys. Acta Proteins Proteomics1751(2),119–139 (2005).
  CASGoogle Scholar
• 67  Bush CA, Sarkar SK, Kopple KD. Circular dichroism of β turns in peptides and proteins. Biochemistry17(23),4951–4954 (1978).
  Medline CASGoogle Scholar
• 68  Gante J. Azapeptides. Synthesis6,405–413 (1989).▪ Early review on azapeptides.
  Google Scholar
• 69  Hess H-J, Moreland WT, Laubach GD. N-[2-isopropyl-3-(L-aspartyl-L-arginyl)-carbazoyl]-L- tyrosyl-L-valyl-L-histidyl-L-prolyl-L-phenylalanine, an isostere of bovine angiotensin II. J. Am. Chem. Soc.85(24),4040–4041 (1963).
  CASGoogle Scholar
• 70  Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. The Lancet360(9327),103–108(2002).
  Medline CASGoogle Scholar
• 71  Zega A, Urleb U. Azapeptides. Acta Chim. Slov.49,640–662 (2002).
  Google Scholar
• 72  Zega A. Azapeptides as pharmacological agents. Curr. Med. Chem.12,589–597 (2005).
  Medline CASGoogle Scholar
• 73  Hart M, Beeson C. Utility of azapeptides as major histocompatibility complex class II protein ligands for T-cell activation. J. Med. Chem.44(22),3700–3709 (2001).
  Medline CASGoogle Scholar
• 74  Andurkar SV, Béguin C, Stables JP, Kohn H. Synthesis and structural studies of aza analogues of functionalized amino acids: new anticonvulsant agents. J. Med. Chem.44(9),1475–1478 (2001).
  Medline CASGoogle Scholar
• 75  Wipf P, Li W, Adeyeye CM, Rusnak JM, Lazo JS. Synthesis of chemoreversible prodrugs of ara-C with variable time-release profiles. Biological evaluation of their apoptotic activity. Bioorg. Med. Chem.4(10),1585–1596 (1996).
  Medline CASGoogle Scholar
• 76  Weber D, Berger C, Eickelmann P, Antel J, Kessler H. Design of selective peptidomimetic agonists for the human orphan receptor BRS-3. J. Med. Chem.46(10),1918–1930 (2003).
  Medline CASGoogle Scholar
• 77  Perona JJ, Craik CS. Structural basis for substrate specificity in the serine proteases. Protein Sci.4(3),337–360 (1995).
  Medline CASGoogle Scholar
• 78  Otto HH, Schirmeister T. Cysteine proteases and their inhibitors. Chem. Rev.97(1),133–172 (1997).
  Medline CASGoogle Scholar
• 79  Kwong AD, Kim JL, Rao G, Lipovsek D, Raybuck SA. Hepatitis C virus NS3/4A protease. Antiviral Res.40(1–2),1–18 (1998).
  Medline CASGoogle Scholar
• 80  Lundblad RL, Bradshaw RA, Gabriel D, Ortel TL, Lawson J, Mann KG. A review of the therapeutic uses of thrombin. Thromb. Haemost.91(5),851–860 (2004).
  Medline CASGoogle Scholar
• 81  Sajid M, McKerrow JH. Cysteine proteases of parasitic organisms. Mol. Biochem. Parasit.120(1),1–21 (2002).
  Medline CASGoogle Scholar
• 82  Barrett A, Rawlings ND. Evolutionary lines of peptidases. Biol. Chem.382(5),727–733 (2001).
  Medline CASGoogle Scholar
• 83  Joyce JA, Baruch A, Chehade J et al. Cathespin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell5(5),443–453 (2004).
  Medline CASGoogle Scholar
• 84  Iwata Y, Mort JS, Tateishi H, Lee ER. Macrophage cathespin L, a factor in the erosion of subchondral bone in rheumatoid arthritis. Arthritis Rheum.40(3),499–509 (1997).
  Medline CASGoogle Scholar
• 85  Lacaille F, Kaleta J, Bromme D. Human and parasitic papain-like cysteine proteases: their role in the physiology and pathology and recent developments in inhibitor design. Chem. Rev.102(12),4459–4488 (2002).
  MedlineGoogle Scholar
• 86  Denault JB, Salvesen GS. Caspases: keys in the ignition of cell death. Chem. Rev.102(12),4489–4500 (2002).
  Medline CASGoogle Scholar
• 87  Bilsland J, Harper S. Caspases and neuroprotection. Curr. Opin. Investig. Drugs3(12),1745–1752 (2002).
  Medline CASGoogle Scholar
• 88  Smalley JW, Birss AJ, Kay HM, McKee AS, Marsh PD. The distribution of trypsin-like enzyme activity in cultures of a virulent and an avirulent strain of Bacteroides gingivalis W50. Oral Microbiol. Immunol.4(3),178–181 (1989).
  Medline CASGoogle Scholar
• 89  Liu C, Sun CZ, Huang HN, Janda K, Edgington T. Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res.63(11),2957–2964 (2003).
  Medline CASGoogle Scholar
• 90  Mitchell WM, Harrington WF. Clostripain. Methods Enzymol.19,635–642 (1970).
  Google Scholar
• 91  Dutta AS, Giles M. Polypeptides. Part XIV. A comparative study of the stability towards enzymes of model tripeptides containing α-aza-amino acids, L-amino acids, and D-amino acids. J. Chem. Soc., Perkin Trans. 1244–248 (1976).
  MedlineGoogle Scholar
• 92  Dutta AS, Giles M, Williams J. Inhibitors of porcine pancreatic elastase. peptides incorporating α-aza-amino acid residues in the P1 position. J. Chem. Soc. Perkin Trans. 11655–1663 (1986).
  Google Scholar
• 93  Zhang R, Durkin JP, Windsor WT. Azapeptides as inhibitors of the hepatitis C virus NS3 protease. Bioorg. Med. Chem. Lett.12(7),1005–1008 (2002).
  Medline CASGoogle Scholar
• 94  Powers JC, Boone R, Carroll DL et al. Reaction of azapeptides with human leukocyte elastase and porcine pancreatic elastase J. Biol. Chem.259(7),4288–4294 (1984).
  Medline CASGoogle Scholar
• 95  Magrath J, Abeles RH. Cysteine protease inhibition by azapeptide esters J. Med. Chem.35(23),4279–4283 (1992).
  Medline CASGoogle Scholar
• 96  Xing R, Hanzlik RP. Azapeptides as inhibitors and active site titrants for cysteine proteinases. J. Med. Chem.41(8),1344–1351(1998).
  Medline CASGoogle Scholar
• 97  Asgian JL, James KE, Li ZZ et al. Aza-peptide epoxides: a new class of inhibitors selective for clan CD cysteine proteases J. Med. Chem.45(23),4958–4960 (2002).
  Medline CASGoogle Scholar
• 98  Frizler M, Stirnberg M, Sisay MT, Gütschow M. Development of nitrile-based peptidic inhibitors of cystein cathepsins. Curr. Top. Med. Chem.10,294–322 (2010).
  Medline CASGoogle Scholar
• 99  Löser R, Frizler M, Schilling K, Gütschow M. Azadipeptide nitriles : highly potent and proteolytically stable inhibitors of papain-like cysteine proteases. Angew. Chem. Int. Ed.47,4331–4334 (2008).
  MedlineGoogle Scholar
• 100  Frizler M, Lohr F, Furtmann N, Kläs J, Gütschow M. Structural optimization of azadipeptide nitriles strongly increases association rates and allows the development of selective cathepsin inhibitors. J. Med. Chem.54(1),396–400 (2011).
  Medline CASGoogle Scholar
• 101  James KE, Asgian JL, Li ZZ et al. Design, synthesis, and evaluation of aza-peptide epoxides as selective and potent inhibitors of caspases-1, -3, -6, and -8 J. Med. Chem.47(6),1553–1574 (2004).
  Medline CASGoogle Scholar
• 102  Ovat A, Muindi F, Fagan C et al. Aza-peptidyl Michael acceptors and epoxide inhibitors- potent and selective inhibitors of Schistosoma mansoni and Ixodes ricinus legumains (asparaginyl endopeptidases) J. Med. Chem.52(22),7192–7210 (2009).
  Medline CASGoogle Scholar
• 103  Ekici OD, Li ZZ, Campbell AJ et al. Design, synthesis and evaluation of aza-peptide Michael acceptors as selective and potent inhibitors of caspases-2, -3, -6, -7, -8, -9 and -10. J. Med. Chem.49(19),5728–5749 (2004).
  Google Scholar
• 104  Sexton KB, Kato D, Berger AB, Fonovic M, Verhelst SHL, Bogyo M. Specificity of aza-peptide electrophile activity-based probes of caspases. Cell Death Diff.14(4),727–732 (2007).▪ Application of azapeptide inhibitors as probes.
  Medline CASGoogle Scholar
• 105  Ekici OD, Gotz MG, James KE et al. Aza-peptide Michael acceptors: a new class of inhibitors specific for caspases and other clan CD cysteine proteseas. J. Med. Chem.47(8),1889–1892 (2004).
  Medline CASGoogle Scholar
• 106  Gotz MG, James KE, Hansell E et al. Aza-peptidyl Michael acceptors. a new class of potent and selective inhibitors of asparaginyl endopeptidases (legumains) from evolutionary diverse pathogens. J. Med. Chem.51(9),2816–2832 (2008).
  MedlineGoogle Scholar
• 107  Ganesan R, Jelakovic S, Campbell AJ et al. Exploring the S4 and S1 prime subsite specificities in caspase-3 with aza-peptide epoxide inhibitors. Biochemistry45(30),9059–9067 (2006).
  Medline CASGoogle Scholar
• 108  Kato D, Verhelst SHL, Sexton KB, Bogyo M. A general solid-phase method for the preparation of diverse aza-peptide probes against cysteine proteases. Org. Lett.7(25),5649–5652 (2005).
  Medline CASGoogle Scholar
• 109  Lee J, Bogyo M. Development of near-infrared fluorophore (NIRF)-labeled activity-based probes for in vivo imaging of legumain. Chem. Biol.5(2),233–243 (2010).
  CASGoogle Scholar